Company Analysis
Sign in

Dyne Therapeutics, Inc. (DYN)

Nasdaq: DYN · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.6
◀ Past 6.0● Present 4.9▶ Future 5.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

54 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Dyne Therapeutics, Inc.’s names, not what it holds today.

Patents granted
54
54 utility, 1976 to Dec 31, 2025
Granted in 2025
18
Against 14 in 2024 and 14 in 2023
Applications published
104
23 of them in 2025
Names they are printed under
1
its own name
By yearGrantedApplications published
'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals43
Biotechnology11
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name1 counted
Dyne Therapeutics, Inc. its own name
US, as the owner printed on each patent
54 granted
104 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 202512,496,352Muscle targeting complexes and uses thereof for treating myotonic dystrophyPharmaceuticalsDyne Therapeutics, Inc.
Nov 25, 202512,478,687United statesPharmaceuticalsDyne Therapeutics, Inc.
Nov 4, 202512,460,011Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering an oligonucleotide to a subjectPharmaceuticalsDyne Therapeutics, Inc.
Oct 14, 202512,440,575Muscle targeting complexes and uses thereof for treating dystrophinopathiesPharmaceuticalsDyne Therapeutics, Inc.
Oct 14, 202512,440,574Muscle targeting complexes and formulations for treating myotonic dystrophyPharmaceuticalsDyne Therapeutics, Inc.
Sep 30, 202512,428,487Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subjectPharmaceuticalsDyne Therapeutics, Inc.
Sep 2, 202512,403,203Muscle targeting complexes and uses thereof for treating dystrophinopathiesPharmaceuticalsDyne Therapeutics, Inc.
Aug 26, 202512,397,062Muscle targeting complexes and uses thereof for treating dystrophinopathiesPharmaceuticalsDyne Therapeutics, Inc.
Jul 29, 202512,370,264Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subjectBiotechnologyDyne Therapeutics, Inc.
Jul 15, 202512,357,703Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skippingPharmaceuticalsDyne Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0382375MUSCLE-TARGETING COMPLEXES AND USES THEREOFPharmaceuticalsDyne Therapeutics, Inc.
Dec 4, 20252025/0367310MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHYPharmaceuticalsDyne Therapeutics, Inc.
Nov 27, 20252025/0360223MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESPharmaceuticalsDyne Therapeutics, Inc.
Nov 6, 20252025/0339553MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHYPharmaceuticalsDyne Therapeutics, Inc.
Oct 2, 20252025/0304710MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MUSCULAR DYSTROPHYPharmaceuticalsDyne Therapeutics, Inc. · patent 12,460,011 granted from it
Sep 25, 20252025/0297024MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESPharmaceuticalsDyne Therapeutics, Inc. · patent 12,478,687 granted from it
Sep 4, 20252025/0276083MUSCLE-TARGETING COMPLEXES AND USES THEREOFPharmaceuticalsDyne Therapeutics, Inc. · patent 12,428,487 granted from it
Aug 28, 20252025/0270340MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYBiotechnologyDyne Therapeutics, Inc.
Aug 7, 20252025/0249119MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIESPharmaceuticalsDyne Therapeutics, Inc. · patent 12,440,575 granted from it
Aug 7, 20252025/0249117DOSING OF MUSCLE TARGETING COMPLEXES FOR TREATING MYOTONIC DYSTROPHYBiotechnologyDyne Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 45 · Biotechnology 8.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton DYN · research, not advice